CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia. The FDA has granted approval to bosutinib (Bosulif) for the treatment of ...

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...

Please provide your email address to receive an email when new articles are posted on . The indication applies to use of the agent by pediatric patients aged 1 year or older with chronic phase ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Europe Chronic Myeloid Leukemia Market and Competitive Landscape Highlights - 2016" report to their offering. The ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Chronic Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017" report to their offering. The results of ...

Chronic myeloid leukemia (CML) is a type of blood cancer. It can affect a person’s red blood cell and platelet count and can also cause a person’s white blood cells to function incorrectly. CML is ...